Clinical Trial

A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes

Study acronym: ACHIEVE-PEDS
Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study looks at how well a medicine called orforglipron works compared to another medicine called dulaglutide in pediatric participants aged 10 to less than 18 years with type 2 diabetes. The study will also check how safe these medicines are and how the body processes them. Participation in the study will last about 61 weeks.
Trial Details
NCT Number NCT07668336
Lead Sponsor Eli Lilly and Company
Conditions Diabetes Mellitus, Type 2
Enrollment 170 participants
Start Date 2026-09
Primary Completion 2030-03 (estimated)
Study Completion 2030-03 (estimated)
Updated on ClinicalTrials.gov 2026-07-20